This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

HomeSupport & ResourcesSupport & ResourcesMaterialsVideosContact us

For BeneFIX® (nonacog alfa) Prescribing Information for Great Britain and Northern Ireland click here. 

For ReFacto AF® (moroctocog alfa) Prescribing Information for Great Britain and Northern Ireland click here.
Adverse event reporting information can be found at the bottom of the page.

Pfizer & Haemophilia: a commitment to treating patients for over 20 years1,2Pfizer's Journey

With more than 20 years' experience treating patients with haemophilia A and B,1,2 ReFacto AF® and BeneFIX® are building on Pfizer's proud heritage in haemophilia care.


Pfizer is committed to the improvement of long-term outcomes for people with haemophilia and the support they receive to manage their conditions.

Through scientific collaboration and long-term investment in new haemophilia therapies, we aim to advance the treatment and address the unmet needs of people with haemophilia.Pfizer's milestones in Haemophilia A and B BeneFIX and ReFacto AF

Find information for your patients with Haemophilia B

    Find out more    Loading

Find information for your patients with Haemophilia A

    Find out more    LoadingExplore More Materials

Access resources and additional information that aim to support you and your patients.

Find out moreLoading Videos

Access resources and additional information that aim to support you and your patients.

Find out moreLoading Button Loading Button Loading Contact us Contact us for more information on BeneFIX and ReFacto AF, and download our FAQ for supply and stock related queries.Find out moreLoading

References

ReFacto AF® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here. Swiech K, et al. Bioengineered. 2017;8(5):462-470BioSpace. 2007. Available at: www.biospace.com/article/releases/wyeth-receives-fda-approval-for-new-benefix-features-that-provide-hemophilia-b-patients-a-simpler-and-more-convenient-preparation-process-for-recombin [Accessed July 2023].Lambert T, et al. Haemophilia. 2007;13(3):233–243.European Medicines Agency. EPAR summary for the  public. https://www.ema.europa.eu/en/documents/overview/refacto-af-epar-summary-public_en.pdf [Accessed July 2023].European Medicines Agency. BeneFIX EPAR – procedural steps taken and scientific information after the authorisation. Available at: https://www.ema.europa.eu/en/documents/procedural-steps-after/benefix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf [Accessed July 2023].Universities in collaboration with Pfizer Inc. in Rare Disease Consortium. 2014 Available at: Universities in Collaboration with Pfizer Inc. in Rare Diseases Consortium - School of Clinical Medicine (cam.ac.uk) [Accessed July 2023].
PP-BEN-GBR-0628. July 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​